Targeted therapy with BRAF, ALK or EGFR kinase inhibitors induces a complex network of secreted factors in human melanoma and lung adenocarcinoma cells, and this therapy-induced secretome stimulates the outgrowth and dissemination of drug-resistant cancer cells and promotes the survival of drug-sensitive cancer cells [13]. Here, BRAF is linked to cancer.